

TENDER NO. BMSIC/DRUGS/19-11

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name : BDR PHARMACEUTICALS INTERNATIONAL PVT. LTD. . Total Number of Pages Submitted in bid documents: 1 TO 255

Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(a)	Tender Fee (Non –Refundable) of Rs 10,000/- in form of Demand Draft drawn in Favor of “Managing Director, Bihar Medical Services and Infrastructure Corporation Limited” payable at Patna. This fee is payable only once for one tender irrespective of items contained therein.	YES	100	YES	-
2	3.(b)	Bidder are required to submit Earnest Money Deposit in the form of Demand Draft / Bank Guarantee drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna. 1.)Upto 5 drugs-Rs1,00,000/- (One Lakh only) 2.)For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only) 3.) For 11 to 15 Drugs Rs 3,00,000/- (One Lakh only) 4.) For 15 to 20 Drugs Rs 4,00,000/- (One Lakh only) 5.) More than 20 Drugs Rs 5,00,000/- (One Lakh only)	YES	101-105	YES	-
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	YES	21	YES	-
4	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	YES	18	YES	-
5	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	YES	26	YES	-
6	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.	YES	160 & 206	YES	-
7	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	YES	112-115	YES	-
8	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	YES	99	YES	-
9	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	YES	109-111	YES	NATURE OF BUSSINESS - PAGE NO-98

my

Ankur

218

TENDER NO. BMSIC/DRUGS/19-11

Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s BDR Pharmaceuticals International Pvt. Ltd. Address:- R.S. No. 578, Near Effluent Channel Road, Vill. Luna, Tal Padra, Dist. Vadodara - 391440 (Gujarat). Total Number of Pages Submitted in bid documents:- 255

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	18	Yes	
2	3.(e)	Power of Attorney or Resolution of Board by which the authorised signatory has been authorized by the bidder firm to sign the documents. Should be submitted.	Yes	26	Yes	
3	3.(f)	Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate as applicable.	No	-	No	Not Submitted
4		Approved product list as per the license issued for quoted product for minimum three years as applicable.	Yes	27-28,29	No	Less than three years. Previous product approval not submitted .
5		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	27-29	No	Manufacturing License certificate not submitted.
6		Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) where ever applicable.	Yes	33-34	No	Not Submitted for FY 2018-2019

Handwritten signature and date: 20/12/2020

Handwritten signature and date: 20/12/2020

Handwritten signature and date: 20/12/2020

Handwritten number: 319

7		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed).	No	—	No	Not Submitted
8		Bidders shall submit self-attested copies of required manufacturing license and approved product list (as applicable) in support of above mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	27-29	No	Not Submitted Manufacturing License Certificate.
9	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three years old valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product are being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA			
10	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product(where ever applicable). Self-attested copies are to be submitted.	NA			
11	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted(where ever applicable). It should be not more than one year old. Selfattested copies are to be submitted.	Yes	89-94	Yes	
12	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule-„M“/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department(where ever applicable). The GMP certificate must not be older than one year from the last date of submission of tender. Self-attested copies are to be submitted.	Yes	98	Yes	

Signature

Signature

Signature

13	3.(k)	Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department highlighting the quoted product section (where ever applicable). Self-attested copies are to be submitted. In case of Importer An affidavit (With Stamp) sworn before first class magistrate/Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/Evidence of import in items of said product with quantity details.	No	—	No	Not Submitted
14	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II.	Yes	24-25	Yes	
15	3.(o)	List of item quoted in prescribed format as per Annexure- C duly signed.	No	—	No	Not submitted
16	5.(j)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV.	Yes	23	Yes	
17	5.(k)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	19-20	No	Incomplete Annexure submitted
18	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	26	Yes	
19	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	NA			

Handwritten signatures and marks:

20	2(d) Explanation	The price quoted by the bidders must not exceed the ceiling price as fixed by NPPA (National Pharmaceutical Pricing Authority) as per the provisions of "Drugs Price Control Order" and the quoted rate should be at least 20% less than its MRP, where ever applicable. In extraordinary case the Managing Director has discretion to take decision. Explanation- In order to ensure procurement of the tendered products at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rates provided to their respective Distributors/Dealers/Wholesalers/Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-Judicial Stamp Paper should be submitted with the Bid."	Yes	17	Yes	
21	Corrigendum II	ANNEXURE-D PERFORMANCE STATEMENT (For the period of last three years)	No	—	No	Not Submitted
22	Corrigendum II	ANNEXURE-E Production Capacity Statement (Self Declaration)	Yes	95	Yes	

Rajesh K

me

low

TENDER NO. BMSIC/DRUGS/19-11

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s BDR Pharmaceuticals International Pvt. Ltd.,

Total Number of Pages Submitted in bid documents:- 255

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	First Approval	Approved Upto	Approved in Brand /Generic Name	
1	8	Everolimus 0.25 mg	Everolimus Tablets 0.25 mg	0.25 mg	0.25 mg	10X10	Not Submitted	Tablet	Tablet	26.06.2019	Not Submitted	Generic	Not Submitted for FY 2018-2019
2	9	Everolimus 0.5 mg	Everolimus Tablets 0.5 mg	0.5 mg	0.5 mg	10X10	Not Submitted	Tablet	Tablet	26.06.2019	Not Submitted	Generic	Not Submitted for FY 2018-2019
3	11	Everolimus 5 mg	Everolimus Tablets 5 mg	5 mg	5 mg	10X10	Not Submitted	Tablet	Tablet	20.01.2015	Not Submitted	Generic	Submitted (at page no. 32)
4	12	Everolimus 10 mg	Everolimus Tablets 10 mg	10 mg	10 mg	10X10	Not Submitted	Tablet	Tablet	20.01.2015	Not Submitted	Generic	Not Submitted for FY 2018-2019, 2017-2018 & 2016 2017

Rajesh B.

mmh

26/07/2020

TENDER NO. BMSIC/DRUGS/19-11

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

**Company Name:- M/s BDR Pharmaceuticals International Pvt. Ltd.,
Total Number of Pages Submitted in bid documents:- 255**

Sheet for verification of licence details

	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	8	Everolimus	25	G/25/2071	—	—	Not Submitted	Not Submitted	16.12.2019	15.12.2022
2	9	Everolimus	25	G/25/2071	—	—	Not Submitted	Not Submitted	16.12.2019	15.12.2022
3	11	Everolimus	25	G/25/2071	—	—	Not Submitted	Not Submitted	16.12.2019	15.12.2022
4	12	Everolimus	25	G/25/2071	—	—	Not Submitted	Not Submitted	16.12.2019	15.12.2022

Note:- Assisted in technical evaluation in reference to letter no.BMSIC/40015/43-2019/7181 dt 18.02.2020 on the basis of documents provided by BMSICL as check list II,III & IV. Provided checklist compiled with due diligence and care.Inspite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discrepancies are observed for rectification.

Rajesh K
20/02/2020

20/02/2020

20/02/2020